交易 Celcuity Inc - CELC 差价合约

交易条件

• 类型: 差价合约
• 点差: 0.45
• 长仓隔夜仓息调整: -0.02237%
• 短仓隔夜仓息调整: 0.00015%
• 隔夜调整仓息时间: 22:00 (UTC)
• 货币: USD
• 最低成交量: 1
• 保证金: 50.00%
• 证券交易所: United States of America
• 交易佣金: 0%
• 保证止损溢价: 1%

主要统计数据

• 前收盘价: 93.58
• 开仓: 94.75
• 1 年变化: 0.48%
• 日区间: 93.05 - 97.91

Celcuity Inc. (NASDAQ: CELC) is a clinical-stage biotechnology company developing companion diagnostics and targeted therapies for cancer. Its lead candidate, gedatolisib, is a dual PI3K/mTOR inhibitor for HR+/HER2- breast cancer, currently in Phase 3 development. Celcuity integrates functional cell analysis with precision oncology to identify responsive patient subgroups. The company offers high-upside exposure to targeted cancer therapeutics and biomarker-driven clinical development.